

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Allowed: September 15, 2004

Art Unit: 1632

Examiner: Valarie E. Bertoglio

Atty. Docket No. 39532-176599

Customer No.

26694
PATENT TRADEMARK OFFICE

In re application of:

R. Jurecic et al.

Appl. No. 10/076,069 /

Confirmation No. 8513

Filed: February 15, 2002

For: "HEPP, A Novel Gene with a Role

in Hematopoietic and Neural

Development"

Amendment Under Rule 312

Attention: Box Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants have not received an initialed copy of the PTO/SB/08A filed September 12, 2002 in the above-referenced application. In a telephonic communication with the undersigned, the Examiner indicated that the Office had no record of having received this form. Enclosed are copies of the Information Disclosure Statement with PTO/SB/08A and cited references filed September 12, 2002, along with a date stamped receipt indicating a date of September 12, 2002.

It is respectfully requested that the examiner consider the references and initial and return the PTO/SB/08A form.

B/A Ufw

Applicant: Roland Jurecic et al. Appl. No. 10/076,069

It is not believed that any fee is due. However, please charge any required fee or credit any refund to our deposit account no. 22-0261 and notify the undersigned.

Respectfully submitted,

Date: 9/22/04

Ann S. Hobbs, Ph.D. Registration No. 36,830

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998 Telephone: (202) 344-4000 Telefax: (202) 344-8300

#582452v1

Venable Filing Number



August 12, 2002 Filing Date

U.S. PTO FEES ENCLOSED

Atty. Docket No.: Re:

Application No.: Patent No.: Trademark:

Opposition/Cancellation No.:

39532-176599		
Roland JURECIC et al.		
10/076,069	Filing Date:	February 15, 2002
	Issue Date:	
	Trademark Reg. No.:	

The following items were received from Venable Washington, D.C., by the U.S. Patent & Trademark Office:

	Check No	Attached
		-
	ψυ.υυ	I VIAI FEES FAIU
Request to Rescing Non-Publication Request	\$0.00	Total Fees Paid
Terminal Disclaimer	:	Notice of Opposition Fee
Request for Corrected Filing Receipt		-
Notice of Opposition		_ TM Renewal Application Fee
Declaration Under 8 and 15		8 and 15 Affidavit
		_ U Allidavit Fee
		8 Affidavit Fee
		_ TM Statement of Use
		The Contament of the
		_ Maintenance Fee
Request for Oral Hearing		
Appeal Brief (in triplicate)		_ Issue Fee
Notice of Appeal		_
Petition/Request for Extension of Time		Petition Fee
Amendment		_ 0.5.7700777977040007700
		Oral Hearing Request Fee
		_ Bitel of Appeal Fee
		Brief on Appeal Fee
		Notice of Appeal Fee
Priority Document-Cert. Copy of		
claims, drawings & declaration)		_ Extension Fee
Application (in Duplicate) (attach copy of specification,	-	_
		IDS Fee
	TO TO SOUTH OF THE PARTY OF THE	_ Recordation/indexing Fee
	1 th	Recordation/Indexing Fee
	—	_ Additional Claim Fee
	1 SEP 1 2 2002 O.	
		_ Surcharge Fee
specification/claims	10. 10	
	TPK	_ raingree
Transmittal Lotter		Filling Fee
	Formal Drawings (Sheets) Invention Declaration National Stage Application Translation of International Application New U.S. TM Application (specimens) Rule 53(d) Continuation or Division Application Rule 53(b) Continuation or Division Application (in Duplicate) (attach copy of specification, claims, drawings & declaration) Priority Document-Cert. Copy of Appln. # Date Assignment w/ Cover Sheet IDS w/ PTO - 1449 (4 references) Response Amendment Petition/Request for Extension of Time Notice of Appeal Appeal Brief (in triplicate) Request for Oral Hearing Confirmation of Hearing Petition Issue Fee Transmittal Certificate of Correction Maintenance Fee Transmittal TM Statement of Use Declaration Under 8 Declaration Under 8 Declaration Under 8 and 15 TM renewal Application Notice of Opposition Request for Corrected Filing Receipt	New U.S. Patent/Design/Application (pages of specification/claims Formal Drawings (Sheets) Invention Declaration National Stage Application Translation of International Application New U.S. TM Application (specimens) Rule 53(d) Continuation or Division Application Rule 53(b) Continuation or Division Application (in Duplicate) (attach copy of specification, claims, drawings & declaration) Priority Document-Cert. Copy of Appln. # Date Assignment w/ Cover Sheet IDS w/ PTO - 1449 (4 references) Response Amendment Petition/Request for Extension of Time Notice of Appeal Appeal Brief (in triplicate) Request for Oral Hearing Confirmation of Hearing Petition Issue Fee Transmittal Certificate of Correction Maintenance Fee Transmittal TM Statement of Use Declaration Under 8 Declaration Under 8 Declaration Under 8 and 15 TM renewal Application Notice of Opposition Request for Corrected Filing Receipt Terminal Disclaimer Request for Non-Publication

DC2DOCS/399817

Rotin to Contan III. Ikne.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Roland JURECIC et al.

SEP 2 3 ZONA POST SOLUTION TO SEP 2

Art Unit: 1645

Appl. No: 10/076,069

Examiner: Not Yet Assigned

Confirmation No: 8513

Filed: February 15, 2002

For: HEPP, A NOVEL GENE WITH A

ROLE IN HEMATOPOIETIC AND NEURAL DEVELOPMENT

Atty. Docket No: 39532-176599

Customer No:

26694
PATENT TRADEMARK OFFICE

Information Disclosure Statement

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. One copy of each of the listed documents is submitted herewith.

Documents A1 – A4 are English language documents so no further statement of relevance need be given.

Applicant: Roland JURECIC et al.

Atty. Docket No.: 39532-176599

The present Information Disclosure Statement is being filed before the mailing date of

the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or

fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and

as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information

Disclosure Statements have been complied with, and it is therefore respectfully requested that

the Examiner consider the documents and make them of record.

Please charge any necessary fee or credit any overpayment in connection with this

Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Date: 9/12/02

Ann S. Hobbs

Registration No. 36,830

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 962-4800

Telefax: (202) 962-8300

ASH/cdw DC2DOCS/399816

					_
Plassa	type a	nhue eign	n /+1	incida	this box

of

Sheet

3 2004	25 J	DT0/00/004 (04 04
_	<u> </u>	PTO/SB/08A (08-00
	શ	Approved for use through 10/31/2002 OMB 0651 002

39532-176599

Approved for use through 10/31/2002. OMB 0 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF CO Under the Paperwork Reduction Act of 1995, no persons are required by spond to a collection of information unless it contains a valid OMB contains.			
Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DICCLOSURE	Application Number	10/076,069	
INFORMATION DISCLOSURE	Filing Date	February 15, 2002	
STATEMENT BY APPLICANT	First Named Inventor	Roland JURECIC et al.	
	Group Art Unit	1645	
(use as many sheets as necessary)	Examiner Name	Not Yet Assigned	

Attorney Docket Number

.e		
	James M. ABDULLAH, et al., "Cloning and Characterizatic flepp, a Novel Gene Expressed Preferentially in Hematopoietic Progenitors and Mature Blood Cells", Blood Cells, Molecules and Diseases, 27 (3), May/June 2001, Pages 667-676	A1
	A2 GenBank Data Entry, Access No. AF322238 (July 5, 2001)	A2
	A3 GenBank Data Entry, Access No. AF 322239 (July 5, 2001)	А3
	A4 GenBank Data Entry, Access No. AK000771 (February 22, 2000)	A4
_		

Examiner	!	Date	
Signature		Considered	

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.